BONESUPPORT(TM) announced that due to internal delays at the U.S. Food and Drug Administration (FDA), the agency has informed BONESUPPORT that a response to the company's De Novo application for marketing authorization for the antibiotic eluting product CERAMENT G for the indication osteomyelitis (bone infection) will be delayed with a few weeks.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
248 SEK | -0.40% | -2.52% | +31.77% |
04-25 | Transcript : Bonesupport Holding AB, Q1 2024 Earnings Call, Apr 25, 2024 | |
04-25 | Bonesupport Holding AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+31.77% | 1.55B | |
+0.82% | 91.94B | |
-1.32% | 38.74B | |
-12.88% | 32.82B | |
+64.77% | 26.66B | |
-16.31% | 15.32B | |
-5.78% | 13.3B | |
-11.38% | 11.65B | |
+173.10% | 10.37B | |
-49.84% | 10.12B |
- Stock Market
- Equities
- BONEX Stock
- News Bonesupport Holding AB
- BONESUPPORT(TM) Announces Delays Within FDA Postpones CERAMENT G De Novo Decision